Transurethral needle ablation of the prostate

Current Opinion in Urology

Volumn 17, Issue 1, 2007, Pages 7-11

  Tubaro, Andrea ^a,c   De Nunzio, Cosimo ^a   Miano, Roberto ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Benign prostatic hyperplasia; Minimally invasive treatment; Prostatic hyperplasia; Transurethral needle ablation

Indexed keywords

ANESTHETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

BLADDER NECK STENOSIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DETRUSOR MUSCLE; ENDOSCOPY; HIGH RISK PATIENT; HUMAN; MICTURITION; MINIMALLY INVASIVE SURGERY; ORGAN SIZE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RADIOFREQUENCY; RESIDUAL URINE; REVIEW; SURGICAL APPROACH; SURGICAL RISK; SYMPTOMATOLOGY; TRANSURETHRAL NEEDLE ABLATION; TREATMENT INDICATION; TREATMENT OUTCOME; URETHRA DISEASE; URINARY TRACT DISEASE; URINE FLOW RATE;

HUMANS; MALE; PROSTATE; PROSTATIC HYPERPLASIA; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 33845438448     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328011ab98     Document Type: Review

References (40)

1. Schulman CC, Zlotta AR, Rasor JS, et al. Transurethral needle ablation (TUNA): safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hyperplasia. Eur Urol 1993; 24:415-423.
2. Schulman CC, Zlotta AR. Transurethral needle ablation of the prostate for treatment of benign prostatic hyperplasia: early clinical experience. Urology 1995; 45:28-33.
3. Ramon J, Lynch TH, Eardley I, et al. Transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia: a collaborative multicentre study. Br J Urol 1997; 80:128-134.
4. Campo B, Bergamaschi F, Corrada P, Ordesi G. Transurethral needle ablation (TUNA) of the prostate: a clinical and urodynamic evaluation. Urology 1997; 49:847-850.
5. Campo B, Bergamaschi F, Muto G, et al. Transurethralneedle ablation (TUNA) of the prostate: preliminary results. Arch Ital Urol Androl 1995; 67:109-113.
6. Millard RJ, Harewood LM, Tamaddon K. A study of the efficacy and safety of transurethral needle ablation (TUNA) treatment for benign prostatic hyperplasia. Neurourol Urodyn 1996; 15:619-628.
7. Harewood LM, Cleeve LK, O'Connell HE, et al. Transurethral needle ablation of the prostate (TUNA): clinical results and ultrasound, endoscopic, and histologic findings in pilot study of patients in urinary retention. J Endourol 1995; 9:407-412.
8. Rosario DJ, Woo H, Potts KL, et al. Safety and efficacy of transurethral needle ablation of the prostate for symptomatic outlet obstruction. Br J Urol 1997; 80:579-586.
9. Chapple CR, Issa MM, Woo H. Transurethral needle ablation (TUNA). A critical review of radiofrequency thermal therapy in the management of benign prostatic hyperplasia. Eur Urol 1999; 35:119-128.
10. Roehrborn CG, Issa MM, Bruskewitz RC, et al. Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study. Urology 1998; 51:415-421.
11. Compendium of Clinical Evidence. TUNA therapy. Aspen Medical Media Ltd.; 2006. Probably the most comprehensive source of evidence of TUNA treatment from a respected author with a large experience in MIT of BPH. Full text references are included.
12. Kahn SA, Alphonse P, Tewari A, Narayan P. An open study on the efficacy and safety of transurethral needle ablation of the prostate in treating symptomatic benign prostatic hyperplasia: the University of Florida experience. J Urol 1998; 160:1695-1700.
13. Minardi D, Galosi AB, Yehia M, et al. Transurethral resection versus minimally invasive treatments of benign prostatic hyperplasia: results of treatments. Our experience. Arch Ital Urol Androl 2004; 76:11-18.
14. Steele GS, Sleep DJ. Transurethral needle ablation of the prostate: a urodynamic based study with 2-year followup. J Urol 1997; 158:1834-1838.
15. Sullivan LD, Paterson RF, Gleave ME, et al. Early experience with transurethral needle ablation of large prostates. Can J Urol 1999; 6:686-691.
16. Zlotta AR, Peny MO, Matos C, Schulman CC. Transurethral needle ablation of the prostate: clinical experience in patients in urinary acute retention. Br J Urol 1996; 77:391-397.
17. Issa MM, Stein B, Benson R, et al. Prospective multicenter study of transperineal prostatic block for transurethral needle ablation of the prostate. Urology 2000; 56:1052-1055.
18. Barmoshe S, Zlotta AR. How do I treat and follow my TUNA patients. World J Urol 2006; 24:397-404 [Epub July 21 2006]. An interesting update on the technique from one of the early adopters.
19. Bouza C, Lopez T, Magro A, et al. Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol 2006; 6:14. A thorough and independent meta-analysis of TUNA evidence from the Agency for Health Technology Assessment. Ministry of Health and Consumers Affairs, Madrid, Spain.
20. Daehlin L, Gustavsen A, Nilsen AH, Mohn J. Transurethral needle ablation for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: outcome after 1 year. J Endourol 2002; 16:111-115.
21. Fujimoto K, Hosokawa Y, Tomioka A, et al. Variations of transition zone volume and transition zone index after transurethral needle ablation for symptomatic benign prostatic hyperplasia. Int J Urol 2003; 10:392-397.
22. Holmes MA, Stewart J, Boulton JB, Chambers RM. Transurethral needle ablation of the prostate: outcome at 1 year. J Endourol 1999; 13:745-750.
23. Murai M, Tachibana M, Miki M, et al. Transurethral needle ablation of the prostate: an initial Japanese clinical trial. Int J Urol 2001; 8:99-105.
24. Namiki K, Shiozawa H, Tsuzuki M, et al. Efficacy of transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia. Int J Urol 1999; 6:341-345.
25. Rodrigo AM, Lopez AE, Monserrat Monfort JJ, et al. Treatment of benign hyperplasia of the prostate using thermal transurethral needle ablation (TUNA). Actas Urol Esp 1997; 21:649-654.
26. Zlotta AR, Giannakopoulos X, Maehlum O, et al. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 2003; 44:89-93.
27. Martin X, Claude A, Colombel M, et al. Treatment of benign prostatic hyperplasia (BPH) by transurethral needle ablation (TUNA) and 36-month follow-up of the retreatment rate. Prog Urol 2005; 15:674-680.
28. Braun M, Mathers M, Bondarenko B, Engelmann U. Treatment of benign prostatic hyperplasia through transurethral needle ablation (TUNA). Review of the literature and six years of clinical experience. Urol Int 2004; 72:32-39.
29. Arai Y, Aoki Y, Okubo K, et al. Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study. J Urol 2000; 164:1206-1211.
30. Bruskewitz R. Management of symptomatic BPH in the US: who is treated and how? Eur Urol 1999; 36 (Suppl 3):7-13.
31. Cimentepe E, Unsal A, Saglam R. Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: results at 18 months. J Endourol 2003; 17:103-107.
32. Hill B, Belville W, Bruskewitz R, et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 2004; 171 (Pt 1):2336-2340.
33. Schatzl G, Madersbacher S, Djavan B, et al. Two-year results of transurethral resection of the prostate versus four 'less invasive' treatment options. Eur Urol 2000; 37:695-701.
34. Roehrborn CG, Burkhard FC, Bruskewitz RC, et al. The effects of transurethral needle ablation and resection of the prostate on pressure flow urodynamic parameters: analysis of the United States randomized study. J Urol 1999; 162:92-97.
35. Tubaro A, Vicentini C, Renzetti R, Miano L. Invasive and minimally invasive treatment modalities for lower urinary tract symptoms: what are the relevant differences in randomised controlled trials? Eur Urol 2000; 38 (Suppl 1):7-17.
36. Muller RM, Thalmann GN, Studer UE. Old and new interventional therapies in the treatment of symptomatic benign prostate hyperplasia (BPH). Ther Umsch 2006; 63:129-134. A balanced view on MITs of BPH.
37. Yu X, McBean AM, Caldwell DS. Unequal use of new technologies by race: the use of new prostate surgeries (transurethral needle ablation, transurethral microwave therapy and laser) among elderly Medicare beneficiaries. J Urol 2006; 175:1830-1835. An interesting issue and a novel point of view which may become more and more relevant also in Europe.
38. AUA Guideline on Management of Benign Prostatic Hyperplasia. Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170(Pt 1):530-547.
39. Chatelain C, Denis L, Foo KT, et al. Benign prostatic hyperplasia. Plymouth: Health Publications Ltd; 2001.
40. De La Rosette J, Alivizatos G, Madersbacher S, et al. Guidelines of benign prostatic hyperplasia. http://www.uroweb.nl/files/uploaded_files/ guidelines/11%20BPH.pdf; 2006. The newly updated version of the EAU Guidelines on Benign Prostatic Hyperplasia from a great team of experts directed by one of the leading authorities in the field. A must read for all European urologists. A reference in the field.